Last reviewed · How we verify
Smartject Device delivery of Golimumab
Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Smartject Device delivery of Golimumab |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Golimumab is a fully human monoclonal antibody that targets TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-α, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. The Smartject device is an auto-injector delivery system that enables patient self-administration of the drug.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Ulcerative colitis
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Nasopharyngitis
- Headache
- Increased infection risk (serious infections)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: